Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

lation phase, expected during the second quarter of 2014, with final study results expected in the second half of 2014. Future development plans for BL-8040 include entering into additional hematological indications, including the commencement of clinical studies in stem cell mobilization and chronic myeloid leukemia during the first half of 2014."

Dr. Gautam Borthakur, the principal investigator from the world-renowned MD Anderson Cancer Center in Houston, stated, "AML is a disease with a clear need for new and more effective treatments. Current options are rather limited, and the five-year survival rate is low compared to many other blood cancers. This is particularly true with respect to patients with relapsed or refractory diseases. The initial results of the BL-8040 Phase 2 trial show a remarkable apoptotic effect of the drug on AML cancer cells, and the drug is exceptional in its ability to induce both mobilization of cancer cells from the bone marrow, as well as a concomitant cell death effect. I therefore have high hopes that this drug will become an important addition to the limited drug arsenal for AML treatment."

About BL-8040
BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia and other hematological indications. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in retention of cancer cells in the bone marrow, tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 18 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile at all doses tested and was high
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015   InspireMD, Inc. (NYSE MKT: ... protection systems ("EPS"), today announced that its CGuard TM ... principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... c A roti D revascularization I n symptomatic ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/22/2015)... , May 22, 2015 ... clinical research unit with a worldwide reputation for ... its frequent publications in peer reviewed medical journals. ... stakeholders and regulators in discussions about rules for ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin ... today announced that it has entered into a definitive ... novel technology for use in the development of subunit ...  The technology is the subject of several United States ...
... PARSIPPANY, N.J., Jan. 27, 2011 Significant flooding occurred ... and early January 2011.  Thousands of residents were affected. ... was launched on 29 December 2010, by Premier of ... who pitched in to help their fellow citizens clean-up ...
Cached Medicine Technology:Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology 2Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology 3Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology 4DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
(Date:5/22/2015)... May 22, 2015 Wimbledon Health Partners, ... electrocardiogram (EKG), echocardiogram and NCV testing , is ... highly respected All American National athlete, to the Wimbledon ... find the high level of testing and information it ... and their athletic trainers, this way they can focus ...
(Date:5/22/2015)... AZ (PRWEB) May 22, 2015 In ... Olympics, Parker and Sons is offering to donate $5 ... installing an AC unit or water softening system. Customers ... behalf; Parker and Sons gets business; and the Special ... , The Special Olympics helps over 4.4 million athletes, ...
(Date:5/22/2015)... 2015 Co founders Greenlee and James Chapko, ... general dentists to immediately deliver fully integrated dental implant services ... of the medical surgeon. , The Center, whose name ... general dentists from placing dental implants. These 6 roadblocks ... introduce the surgical placement of dental implants into his or ...
(Date:5/22/2015)... Maine (PRWEB) May 22, 2015 ... single-use swabs for the medical, diagnostic, environmental, and ... entire line of products in the US. At ... their operations outside the US, Puritan remains committed ... products at their Guilford, Maine facility. , Since ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2
... now have many more treatment options than in the ... derived by modifying substances found in humans or animals, ... the symptoms. The cost of biologic DMARDs is a ... 100 times more than a year,s supply of older, ...
... million people in America,have some form of epilepsy, a ... Treatment can be tough to get, though, for people,without ... This National Epilepsy Awareness Month, Pfizer wants to tell,you ... and women get,prescription medicines for free or at a ...
... Study finds twice the incidence of ,food insecurity, , , TUESDAY, ... smokers are more likely to be underfed and undernourished, a ... members of smoking households, but children feel the impact the ... at New York University School of Medicine. , "We know ...
... BlueCross announced the,launch of the only Blue branded dental ... Dental. No specific date was set for the,rollout of ... be available to,customers in 2009., "We believe that ... in our region because it carries the promise of ...
... DIEGO, Nov. 4 Accumetrics, Inc. announces the,appointment of ... of Operations and R&D. Mr. Dippel will oversee the ... are excited to have Bill join our team," said ... 33 years of,operations and R&D experience in the healthcare ...
... The American Society of,Hematology (ASH), the world,s largest ... to its Executive Committee, the,governing body of the ... January 2009., J. Evan Sadler, MD, PhD, ... by successive terms as president-elect and president. Charles,Abrams, ...
Cached Medicine News:Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D 2Health News:New Leadership Elected to the American Society of Hematology 2
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Female High Waist Briefs...
Medicine Products: